Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna. (April 2017) - Follo, M.Y.; Pellagatti, A.; Armstrong, R.N.; Mongiorgi, S.; Astolfi, A.; Indio, V.; Ratti, S.; Clissa, C.; Barraco, M.; Parisi, S.; Manzoli, L.; Pession, A.; et al.